Home
Live Updates
Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma : vimarsana.com
Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma
Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.
Related Keywords
United States ,
Ibrutinib Imbruvica ,
Brads Kahl ,
Pirtobrutinib Jaypirca ,
Oncology Division ,
Washington University School Of Medicine ,
Department Of Medicine ,
National Comprehensive Cancer Network ,
Washington University School ,
Mantle Cell Lymphoma ,
Cmcl ,
Btk Inhibitors ,
Soho ,
vimarsana.com © 2020. All Rights Reserved.